Lincoln Pharmaceuticals Ltd Targets Revenue of Rs. 1,000 Crore Within the Next Three Years
Published on: Nov. 14, 2025, 10:15 a.m. | Source: The Tribune
Ahmedabad (Gujarat) [India], November 14: Lincoln Pharmaceuticals Limited (BSE: 531633, NSE: LINCOLN), one of India's leading healthcare companies, has reported a consolidated net profit of Rs. 20.01 crore for the Q2 FY 2025-26. Total income for the quarter ended September 2025 was reported at Rs. 170.60 crore, and EBITDA was reported at Rs. 32.66 crore. Shareholders at the 31st Annual General Meeting (AGM) approved a dividend of Rs. 1.80 per share (18%) for the FY 2024-25.
